MedeasyMEDEASYREVIEWOpen Medeasy
Publication library

References

Sources cited across Medeasy Review editions.

From Evidence to Better Decisions

References are included in the original published pages. Read the article from Issue 03.

Papers Worth Knowing

  1. Lassen et al. NEJM Evidence (Aug 29, 2026). doi:10.1056/EVIDoa2600272.
  2. Sasieni et al. N Engl J Med (Sep 22, 2026). doi:10.1056/NEJMoa2505723.
  3. Schrappe et al. N Engl J Med (2026);395:1075–89. doi:10.1056/NEJMoa2604166.
  4. Dauvilliers et al. N Engl J Med (2026);395:1166–79. doi:10.1056/NEJMoa2601598.

Diabetes, Earlier.

  1. Davies MJ, et al. ADA/EASD 2026 Consensus Report. Diabetes Care. 2026. doi:10.2337/dci26-0141.
  2. Davies MJ, et al. ADA/EASD Consensus Report. Diabetes Care. 2022. doi:10.2337/dci22-0034.
  3. PCEDM. Outpatient T2DM Management CPG, Part 2b. DOH Guidelines Platform. 2026.

Septic Shock: Have We Been Giving Too Much Fluid?

  1. ARISE FLUIDS Investigators. N Engl J Med. 2026;395:1387–1398. doi:10.1056/NEJMoa2516225.
  2. CLOVERS Investigators. N Engl J Med. 2023;388:499–510. doi:10.1056/NEJMoa2212663.
  3. Meyhoff TS, et al. N Engl J Med. 2022;386:2459–2470. doi:10.1056/NEJMoa2202707.
  4. Prescott HC, et al. Surviving Sepsis Campaign 2026. Intensive Care Med. 2026;52:863–936. doi:10.1007/s00134-026-08361-1.

COPD Beyond Inhalers

  1. Sciurba FC, et al. N Engl J Med. 2026. doi:10.1056/NEJMoa2606998. Funded by AstraZeneca. Tozorakimab remained investigational at this review.
  2. BOREAS: NEJMoa2303951 · NOTUS: NEJMoa2401304 · MATINEE: NEJMoa2413181 OBERON/TITANIA: NEJMoa2606998 | Trials funded by respective manufacturers.
  3. GOLD 2026 · Sciurba et al., NEJM 2026 (NEJMoa2606998) · AstraZeneca CHEST 2026 release (sponsor report; preliminary).

Antibiotic Resistance: The Philippine Reality

  1. 1. RITM/DOH. ARSP 2025 Annual Report Data Summary. 2. WHO. GLASS Manual, 2023. 3. IDSA. Guidance on antimicrobial-resistant Gram-negative infections, 2024.
  2. DOH-RITM. ARSP 2025 Annual Report (published July 2026). Figures 89 (p64), 108 (p79), 143 (p108), and 8 (p15).
  3. DOH-RITM ARSP 2025 (2026); DOH AO 2023-0011; CDC Stewardship (2019); IDSA ASB (2019).

The Fatty Liver Trap: What Normal Liver Enzymes Can Miss

  1. ADA, Standards of Care in Diabetes 2026 (doi:10.2337/dc26-S004); EASL–EASD–EASO MASLD Guideline, J Hepatol 2024 (doi:10.1016/j.jhep.2024.04.031).
  2. ADA Standards of Care 2026, Sec. 4; EASL–EASD–EASO MASLD CPG 2024.

AI in Eye Care: Better Screening—or Simply Fewer Referrals?

  1. 1. Wolf RM et al. Nat Commun. 2024;15:421. doi:10.1038/s41467-023-44676-z. 2. Gil O et al. Br J Ophthalmol. 2026. doi:10.1136/bjo-2025-328991. 3. ADA Standards 2026.
  2. 1. Chen KY et al. npj Digit Med. 2026;9:400. doi:10.1038/s41746-026-02627-0. 2. Eduardo MKDG, Pajarillo JR. Acta Med Philipp. 2026;60(17). Retrospective validation.

Two Studies. Two Clinical Lessons.

  1. 1. Palmer DJ, et al. N Engl J Med. 2026;395:1090–1099. doi:10.1056/NEJMoa2605659.
  2. 2. Sahel JA, et al. N Engl J Med. 2026;395:1399–1408. doi:10.1056/NEJMoa2602215.

Monday Morning Medicine

References are included in the original published pages. Read the article from Issue 03.

ESC 2026 — Five Findings Worth Knowing

References are included in the original published pages. Read the article from Issue 02.

Colchicine: Why Do the Trials Disagree?

References are included in the original published pages. Read the article from Issue 02.

SINGLE-AF: Do We Anticoagulate Too Late?

References are included in the original published pages. Read the article from Issue 02.

Baxdrostat: The Aldosterone Comeback

References are included in the original published pages. Read the article from Issue 02.

Target Engagement Is Not Enough

References are included in the original published pages. Read the article from Issue 02.

TAVI First or PCI First?

References are included in the original published pages. Read the article from Issue 02.

Can an App Really Lower Blood Pressure?

References are included in the original published pages. Read the article from Issue 02.

Monday Morning Medicine

References are included in the original published pages. Read the article from Issue 02.

Four Studies. Real Impact.

References are included in the original published pages. Read the article from Issue 02.

Use Medeasy. Make Everyday Practice More Rewarding.

References are included in the original published pages. Read the article from Issue 02.

Medicine, Reimagined

  1. Medeasy Review, Issue 01, pp. 4-6.

The Peptide Revolution: Retatrutide

  1. Jastreboff AM, et al. N Engl J Med. 2023;389:514-526.
  2. Medeasy Review, Issue 01, pp. 7-9.

Dapagliflozin Beyond Glycemic Control

  1. McMurray JJV, et al. N Engl J Med. 2019;381:1995-2008.
  2. Heerspink HJL, et al. N Engl J Med. 2020;383:1436-1446.
  3. Solomon SD, et al. N Engl J Med. 2022;387:1089-1098.

Inclisiran & Evolocumab: Different Paths, Same Goal

  1. Ray KK, et al. N Engl J Med. 2020;382:1507-1519.
  2. Sabatine MS, et al. N Engl J Med. 2017;376:1713-1722.

ELEVATE: A Deep Dive

  1. ELEVATE Trial. N Engl J Med. 2026; online July 8, 2026.
  2. ClinicalTrials.gov: NCT05341583.

Beyond BMI: A More Complete View of Obesity

  1. Wilding JPH, et al. Nat Rev Endocrinol. 2026;22:453-470.
  2. Busetto L, et al. Nat Med. 2024;30:2395-2399.

Stage 1 Hypertension: Treat Early, Treat Smart

  1. American Heart Association. 2025 High Blood Pressure Guideline.
  2. International Society of Hypertension. Global Hypertension Practice Guidelines. 2025.

Lipids Reimagined

  1. Blumenthal RS, et al. Circulation. 2026;153:e1154-e1276.

Type 2 Diabetes in 2026

  1. American Diabetes Association. Standards of Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1).

Your Watch Found AF. Now What?

  1. January CT, et al. 2026 AHA/ACC/HRS Guideline for Atrial Fibrillation.
  2. Hindricks G, et al. Eur Heart J. 2026.

How Much Can You Trust Smartwatch Blood Pressure?

  1. Sharman JE, et al. Circulation. 2025.
  2. Whelton PK, et al. Circulation. 2025.
  3. Bohm M, et al. Eur Heart J. 2024.